{"DataElement":{"publicId":"7789388","version":"1","preferredName":"Prostate Carcinoma Histologic Subtype","preferredDefinition":"The subtype of prostate carcinoma defined by the microscopic physical features of cells and their surrounding extracellular environment.","longName":"7789310v1.0:7789349v1.0","context":"MCL","contextVersion":"1","DataElementConcept":{"publicId":"7789310","version":"1","preferredName":"Prostate Carcinoma Histologic Subtype","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._The classification of tumors based on their histology.","longName":"2744055v1.0:7029851v1.0","context":"MCL","contextVersion":"1","ObjectClass":{"publicId":"2744055","version":"1","preferredName":"Prostate Carcinoma","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8AEEC8-FDF2-03F8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-23","modifiedBy":"ONEDATA","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7029851","version":"1","preferredName":"Histologic Subtype","preferredDefinition":"The classification of tumors based on their histology.","longName":"C19790","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic Subtype","conceptCode":"C19790","definition":"The classification of tumors based on their histology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95FF4648-EC97-0C4B-E053-F662850AA284","latestVersionIndicator":"Yes","beginDate":"2019-10-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-28","modifiedBy":"ONEDATA","dateModified":"2019-10-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CD1168B4-B670-7ED8-E053-4EBD850AC5DE","latestVersionIndicator":"Yes","beginDate":"2021-09-28","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-28","modifiedBy":"COLBERTM","dateModified":"2022-02-28","changeDescription":"2/28/22 mr Released per SME.   9/29/21 mr Created for MCL prostate. Per MCL DD","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7789349","version":"1","preferredName":"Prostate Carcinoma Histologic Subtype Type","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._The classification of tumors based on their histology._Something distinguishable as an identifiable class based on common qualities.","longName":"7789349v1.0","context":"MCL","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Mucinous","valueDescription":"Mucinous Prostate Carcinoma","ValueMeaning":{"publicId":"7797946","version":"1","preferredName":"Mucinous Prostate Carcinoma","longName":"7797946","preferredDefinition":"Containing or resembling mucin.: One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucinous","conceptCode":"C14163","definition":"Containing or resembling mucin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE3D249A-7B59-2EEC-E053-4EBD850A0603","latestVersionIndicator":"Yes","beginDate":"2021-10-13","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-13","modifiedBy":"ONEDATA","dateModified":"2021-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE3D249A-7B72-2EEC-E053-4EBD850A0603","beginDate":"2021-10-13","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-13","modifiedBy":"ONEDATA","dateModified":"2021-10-13","deletedIndicator":"No"},{"value":"Ductal","valueDescription":"Ductal Prostate Carcinoma","ValueMeaning":{"publicId":"7797947","version":"1","preferredName":"Ductal Prostate Carcinoma","longName":"7797947","preferredDefinition":"Related to, or having the quality of, a duct.: One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ductal","conceptCode":"C25732","definition":"Related to, or having the quality of, a duct.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE3D249A-7B7F-2EEC-E053-4EBD850A0603","latestVersionIndicator":"Yes","beginDate":"2021-10-13","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-13","modifiedBy":"ONEDATA","dateModified":"2021-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE3D249A-7B98-2EEC-E053-4EBD850A0603","beginDate":"2021-10-13","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-13","modifiedBy":"ONEDATA","dateModified":"2021-10-13","deletedIndicator":"No"},{"value":"Not reported","valueDescription":"Not Reported","ValueMeaning":{"publicId":"2572231","version":"1","preferredName":"Not Reported","longName":"2572231","preferredDefinition":"Not provided or available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E734-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-11-16","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD0FC7DF-D16E-4294-E053-4EBD850A3491","beginDate":"2021-09-28","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-28","modifiedBy":"ONEDATA","dateModified":"2021-09-28","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"5682953","version":"1","preferredName":"Unknown","longName":"5682953","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4645-0FC6-0802-E053-F662850AB305","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD0FC7DF-D178-4294-E053-4EBD850A3491","beginDate":"2021-09-28","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-28","modifiedBy":"ONEDATA","dateModified":"2021-09-28","deletedIndicator":"No"},{"value":"Small cell carcinoma","valueDescription":"Prostate Small Cell Carcinoma","ValueMeaning":{"publicId":"2581148","version":"1","preferredName":"Prostate Small Cell Carcinoma","longName":"2581148","preferredDefinition":"A neuroendocrine carcinoma of the prostate gland with unfavorable prognosis. It is composed of small cells containing neurosecretory granules.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Small Cell Neuroendocrine Carcinoma","conceptCode":"C6766","definition":"A rare small cell neuroendocrine carcinoma that arises from the prostate gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A09-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"COOPERM","dateModified":"2020-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD0FC7DF-D182-4294-E053-4EBD850A3491","beginDate":"2021-09-28","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-28","modifiedBy":"ONEDATA","dateModified":"2021-09-28","deletedIndicator":"No"},{"value":"Neuroendocrine","valueDescription":"Prostate Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"6814231","version":"1","preferredName":"Prostate Neuroendocrine Carcinoma","longName":"6814231","preferredDefinition":"A small cell or rarely a large cell neuroendocrine carcinoma that arises from the prostate gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Neuroendocrine Carcinoma","conceptCode":"C158912","definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the prostate gland. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D430FCC-01AA-40BD-E053-F662850AF8E0","latestVersionIndicator":"Yes","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD0FC7DF-D196-4294-E053-4EBD850A3491","beginDate":"2021-09-28","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-28","modifiedBy":"ONEDATA","dateModified":"2021-09-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7789348","version":"1","preferredName":"Prostate Carcinoma Histologic Subtype Type","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.:The classification of tumors based on their histology.:Something distinguishable as an identifiable class based on common qualities.","longName":"C4863:C19790:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Histologic Subtype","conceptCode":"C19790","definition":"The classification of tumors based on their histology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD0FC7DF-D147-4294-E053-4EBD850A3491","latestVersionIndicator":"Yes","beginDate":"2021-09-28","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-28","modifiedBy":"ONEDATA","dateModified":"2021-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CD0FC7DF-D158-4294-E053-4EBD850A3491","latestVersionIndicator":"Yes","beginDate":"2021-09-28","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-28","modifiedBy":"COLBERTM","dateModified":"2022-02-28","changeDescription":"2/28/22 mr Released per SME.   9/28/21 mr Created for MCL prostate. Per MCL DD.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506113","version":"1","longName":"Prostate","context":"MCL","ClassificationSchemeItems":[{"publicId":"7781145","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]},{"publicId":"6437797","version":"1","longName":"Pre-Cancer Atlas Pilot","context":"MCL","ClassificationSchemeItems":[{"publicId":"7001794","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]}],"AlternateNames":[{"name":"histologic_subtype","type":"MCL Alt Name","context":"MCL"}],"ReferenceDocuments":[{"name":"MCL-PCA-prostate-1","type":"Alternate Question Text","description":"Histologic subtype","url":null,"context":"MCL"},{"name":"MCL-Template Name","type":"Data Collection Template","description":"prostate_v0_13aug2020.xlsx","url":"https://mcl.nci.nih.gov/resources/standards/mcl-cdes","context":"MCL"},{"name":"Histologic subtype","type":"Preferred Question Text","description":"Histologic subtype","url":null,"context":"MCL"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CD11D9C9-1885-3D40-E053-4EBD850A768A","latestVersionIndicator":"Yes","beginDate":"2021-09-28","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-09-28","modifiedBy":"COLBERTM","dateModified":"2022-02-25","changeDescription":"2/25/22 mr Released per SME.   10/26/21 mr Edited definition.   10/13/21 Modified PVs per MCL PCA prostate DCT.   9/28/21 mr Created for MCL prostate.  Added alt name, AQT, ref doc, per MCL DD.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}